In cells, ATP13A3‐mediated polyamine uptake can be prevented by AMXT 1501, a polyamine uptake inhibitor currently in phase I/II clinical trials for cancer, indicating that preventing polyamine uptake via ATP13A3 may at least partially explain the mode of action of the drug. Here, ATP13A3 is linked to cancer.